Top Pulmonology/Respirology Research Papers

Overall: A large synthesis of prospective management studies supports adaptive D-dimer thresholds as a practical way to reduce chest imaging while maintaining very low rates of missed clinically important thromboembolism.

Overall: A strong phase 3 trial shows exceptionally large weight loss with meaningful improvements in knee pain and sleep-apnea severity, but incomplete safety reporting and real-world access burdens temper its immediate impact.

Overall: Two large replicate randomized trials found a substantial and consistent reduction in clinically important COPD exacerbations without an apparent adverse-event penalty, although monthly biologic administration may limit routine uptake.

Overall: A strong randomized phase 3 trial reports a large and precise survival benefit with fewer severe adverse events, supporting meaningful practice change despite open-label conduct and unresolved access and implementation details.

Overall: This small but rigorous randomized trial found a large, patient-important improvement in IPF-related cough with an accessible treatment, offset by increased adverse effects and a need for broader confirmation.

Overall: This multicenter randomized trial found a clinically substantial reduction in short-term death, recurrent embolism, or decompensation without higher aggregate bleeding, but open-label assessment, few events, two intracranial hemorrhages, and the need for specialized catheter-based care temper the result.

Overall: A strong synthesis of randomized evidence demonstrates clinically meaningful exacerbation reductions with limited reported harms, but direct impact on routine US primary care is moderated by the specialist-oriented population and treatment context.

Overall: Multicomponent rehabilitation produced a large improvement in ventilator weaning with no detected DVT excess, but the small single-center Chinese trial and insufficient implementation detail limit immediate practice change.

Overall: A strong multicenter randomized trial found no symptomatic or utilization benefit from azithromycin, offering clear evidence to reduce unnecessary antibiotic treatment for acute preschool wheezing.

Overall: Large, consistent cohorts support a simple two-year risk category, but its ability to improve patient outcomes remains untested.